Skip to main content
. 2021 May 25;11:10883. doi: 10.1038/s41598-021-90451-9

Figure 3.

Figure 3

ß2 sites are co-targets for the treatment of ALL. (a) Cells were co-treated with ONX-0914 and LU-102 for 1 h, or treated with ONX-0914 for 1 h, followed by 47 h treatment with LU-102, and cell viability was assessed with Alamar Blue (top panels, n = 2–5). Combination indexes were calculated using CalcuSyn software (bottom panels). (b) Top panels, cells were treated with LU-102 for times indicated (left panel) or for 48 h (right panel). Cell viability was assessed with Alamar Blue 48 h after start of the treatments (n = 2). Bottom panel, inhibition of different active sites was measured with fluorogenic substrates in extracts of cells continuously treated with LU-102 (n = 2).